{
    "root": "30cce5b1-ed48-5bf2-e063-6394a90aaf1d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Levothyroxine Sodium",
    "value": "20250320",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "LEVOTHYROXINE SODIUM",
            "code": "9J765S329G"
        }
    ],
    "indications": "hypothyroidism levothyroxine sodium tablets indicated adult pediatric patients , including neonates , replacement therapy primary ( thyroidal ) , secondary ( pituitary ) , tertiary ( hypothalamic ) congenital acquired hypothyroidism . pituitary thyrotropin ( thyroid-stimulating hormone , tsh ) suppression levothyroxine sodium tablets indicated adult pediatric patients , including neonates , adjunct surgery radioiodine therapy management thyrotropin-dependent well-differentiated thyroid cancer . limitations levothyroxine sodium tablets indicated suppression benign thyroid nodules nontoxic diffuse goiter iodine-sufficient patients benefits overtreatment levothyroxine sodium tablets may induce hyperthyroidism [ ( 5.1 ) ] . levothyroxine sodium tablets indicated treatment hypothyroidism recovery phase subacute thyroiditis .",
    "contraindications": "administer daily , preferably empty stomach , one-half one hour breakfast . ( 2.1 ) administer least 4 hours drugs known interfere absorption . ( 2.1 ) evaluate need dose adjustments regularly administering within one hour certain foods may affect absorption . ( 2.1 ) advise patients stop biotin biotin-containing supplements least 2 days assessing tsh and/or t4 levels . ( 2.2 ) starting dose depends variety factors , including age , body weight , cardiovascular status , concomitant medications . peak therapeutic effect may attained 4 6 weeks . ( 2.2 ) full prescribing information dosing patient . ( 2.3 ) adequacy therapy determined periodic monitoring tsh and/or t4 well status . ( 2.4 )",
    "warningsAndPrecautions": "supplied levothyroxine sodium tablets usp round , colored , scored debossed following debossing details one side break-line side . supplied follows : strength ( mcg ) color/shape debossing details ndc # bottles 30 ndc # bottles 100 ndc # bottles 500 ndc # bottles 1000 88 olive/round l19 68071-3814-3 storage handling store 25°c ( 77°f ) ; excursions permitted 15° 30°c ( 59° 86° f ) [ usp controlled room temperature ] . levothyroxine sodium tablets usp protected light moisture .",
    "adverseReactions": "levothyroxine sodium tablets contraindicated patients uncorrected adrenal insufficiency [ ( 5.4 ) ] .",
    "indications_original": "Hypothyroidism\n                  \n                  Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.\n                  \n                     Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression\n                  \n                  Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.\n                  \n                     Limitations of Use\n                  \n                  \n                     Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism\n  \n   [see Warnings and Precautions (\n   \n    5.1)]\n  \n   .\n \n  \n                     Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.",
    "contraindications_original": "Administer once daily, preferably on an empty stomach, one-half to one hour before breakfast. ( 2.1 ) Administer at least 4 hours before or after drugs that are known to interfere with absorption. ( 2.1 ) Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption. ( 2.1 ) Advise patients to stop biotin and biotin-containing supplements at least 2 days before assessing TSH and/or T4 levels. ( 2.2 ) Starting dose depends on a variety of factors, including age, body weight, cardiovascular status, and concomitant medications. Peak therapeutic effect may not be attained for 4 to 6 weeks. ( 2.2 ) See full prescribing information for dosing in specific patient populations. ( 2.3 ) Adequacy of therapy determined with periodic monitoring of TSH and/or T4 as well as clinical status. ( 2.4 )",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  Levothyroxine sodium tablets USP are round, colored, scored and debossed with following debossing details on one side and break-line on other side. They are supplied as follows:\n                  \n                     \n                        \n                        \n                        \n                        \n                        \n                        \n                        \n                     \n                     \n                        \n                           \n                              Strength (mcg)\n                           \n                           \n                              Color/Shape\n                           \n                           \n                              Debossing Details\n                           \n                           \n                              NDC# for bottles of 30\n                           \n                           \n                              NDC # for bottles of 100\n                           \n                           \n                              NDC # for bottles of 500\n                           \n                           \n                              NDC # for bottles of 1000\n                           \n                        \n                        \n                           \n                           \n                           \n                           \n                           \n                           \n                           \n                        \n                        \n                           88\n                           Olive/Round\n                           L19\n                           68071-3814-3\n                           \n                           \n                           \n                        \n                     \n                  \n                  \n                     Storage and Handling\n                  \n                  Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86° F) [see USP Controlled Room Temperature]. Levothyroxine sodium tablets USP should be protected from light and moisture.",
    "adverseReactions_original": "Levothyroxine sodium tablets are contraindicated in patients with uncorrected adrenal insufficiency\n \n  [see Warnings and Precautions (\n  \n   5.4)]\n \n  ."
}